From an ICICI direct report on Lupin in Nov 2016, when the company relaunched this drug.
Methergine (methylergonovine maleate) Oral tablets 0.2 mg are used for the prevention and management of postpartum haemorrhage (PPH). Methergine is the only FDA-approved oral uterotonic and is a preferred oral agent in management of PPH
Also see http://www.lupin.com/lupin-bolsters-us-brands-portfolio-with-methergine-oral-tablets.php
An article in 2016 mentioned Lupin’s branded Methergine could be an $80-100 m annualised opportunity for Lupin in the US market.
In FY17 it achieved a $55-60 million annual rate (link)